Oklo (NYSE:OKLO) is positioned for growth in the US nuclear sector, according to Wedbush analysts, who maintained an ‘Outperform’ rating with a 12-month price target of $150 after the pre-commercialization nuclear firm reported its Q3 financial results.
Shares of Oklo traded up 8.3% post-earnings at $113.
“Oklo is setting the stage for nuclear energy to become widely adopted over the next decade as the AI Revolution data center buildout is driving significant demand for new energy to power these initiatives with necessary computing power expected to grow 10x by 2030,” the analysts wrote.
The analysts highlighted regulatory progress as a major catalyst for Oklo. “The company continues to see regulatory acceleration for its projects with the Department of Energy (DOE) authorizing an approval to construct and operate a nuclear facility creating a modern pathway to get new nuclear plants built quickly with operating facilities having an option to transition to NRC licensing and oversight for full commercial operations,” they noted.
Wedbush also pointed to Oklo’s recent operational progress as a positive indicator for the company’s outlook.
The firm noted that the Aurora project at Idaho National Laboratory broke ground in September and is moving forward under the DOE’s Reactor Pilot Program, with full excavation expected to begin in early January.
They highlighted that the Atomic Alchemy facility is on track to begin operations by July 2026, providing a platform for research and development, supply chain validation, and risk reduction ahead of Oklo’s larger Isotope Production Reactor commercial deployment in Idaho.
The strategic role of Oklo’s fuel capabilities was also highlighted by Wedbush. “The company’s Advanced Fuel Center, which includes a $1.68 billion investment, anchors its fuel supply chain while providing a new authorization pathway to unlock industrial capacity strength in national energy security and improve domestic fuel production under the executive order,” the analysts wrote.
Wedbush concluded: “We maintain our ‘Outperform’ rating and our $150 price target while keeping the company on our IVES AI 30 list as the nuclear energy buildout accelerates throughout this decade.”